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n.  35 Pie DS (%) IAPD (mmHg) 
Pro.procedure 723 +, 17,2 47,t L 24.3 
Post.procodore 3,8 el: t3,3 0 '~' 4,4 
F~llow up (~'7 ~ ~0 month=) 3,2 ~..'1,5 
O8 ~ Diameter Iitonolll!, I~PO ,~ latin.Arm Prenum Difference 
Follow up: At S mesa follow up of 2 yre (27 .+. 20 months) 33/33 pie (97%) 
remained aaympfomstle, One pt (3%) required repeat b~llcon angloplaety for 
rootenosls 10 months alter the procedure, 1~,0 (5,7%) pie died oi congestive 
heart failure nt 4 end 20 months mspeetlvely, 
Concision: Stinting of the subclavian and Innomlnete a~lo~ Dan be 
~¢hlaved with high technical succaos and provides a durable ellnleal moult, 
[• Coronary 8tenting: Highlighted AbMraet 
Seaolon With Oleeuulon of Current 
I~mpe©tlvn 
Mondw, Mamh 30, 1998, 10:30 ~,m,-Noon 
Georgia World Congress Center, Lecture Hall 3 
10:45 
~ Corone~ 8t~nta Improve Outcome In A©uts 
Myognr¢llnl Infarotlen: Imm~lnt~ and Long 1~rm 
Relult8 Of the GRRMI 1YIM 
A,E, Rodriguez, V,H, aemaKll, O,A, Santaera, C, Meuvecln, F, Ayala, 
J, Mafllnez, G, Rouble. I,F, Palaclos, J,A, Ambrose, On behattot he GRAMI 
itlve~tlgator& Carff~c Unit Ofamef~fVArchomna H~pifal, 8~rlo~ Alma, 
Aq~mtln~ 
~;~n~:  Sleeting aa primanj therapy In my~ardlal infamtlon (AMI) is 
con*,mvemlsl due to the preaen~ of thmmbua, 
M~O~:  104 ~0e~lta pmaentlog with AMI <24 houm after onset were 
mndoml~i tO tWO groups; The Stont group (n = 52) was treated acutely with 
a GRit stem, The PTCA group (n ,. 52) received conventional angloplaety, All 
lesions were suitable for slanting, Baseline demographic, and anglographic 
charac, teflMtcs were similar In the two groups, Pre,.'edural success was de- 
fined as no laboratory death or emergent CABG, TIMI 2 or 3 flow, and residual 
stenosls ~30% for PTCA, or -20% for atont, PTCA patients were eligible 
to cross over to stont for acute closure, type C,F dissections, and resldual 
etenosis ~30%,, ~zt surviving patients underwent a 7 day aogtogram, Long 
tern1 follow-up was also available. 
Hospital RoI~ulIs Stoat PTCA p-Value 
(n ~ 5~t (n ~ 52) 
ProcoQur~t suc,.'~as: 98% 94%, NS 
ELa~lt out stentl~ 9 25% 
Any n~or a~rse event 38% 102% 0.03 
TiM| 3 Row at ? daY~ 98% 833% 0,028 
At one year (range 8-17 months) freedom from major clinical events was 
higher in the Slant ve. PTCA groups (82,7% and 65,4% respectively, p = 
0.002). Target vessel revasculartzatlon was 9,6% and 13.4% ~n Slant and 
PTCA groups respectively (p = NS). 
Collusions: A coronary stont as pdmary therapy in AMI reduces acute 
complications and improves TIMI 3 flow. On folicw-up freedom from major 
clinical events is also better. 
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~ Perhproce¢lural QCA Fol lowing Paimaz-Schatz Stent 
Implantation Predicts Restenosis Rate et 6 Months:  
Res~l!t of  e Mets-ana!ys!s of  BENESTENT.i, 
BENESTENT-Ii Pilot, BENESTENT.II and MUSIC 
P,W, Serruys, J, Kootstra, R. Melkert, P, de Jaegere, M van den Brand, 
M. Morel. Thoraxcenter, Cardia/ysis, Rotterdam, NL, USA 
Between 91 and 97 four trials using the same slant have been coordinated 
in Cardlalysis. QCA has been performed on 804 lesions, using the same 
methods (,I analysis (CAAS system). M~asurement of MLD, interpolated ref. 
erenca diameter and DS% (pie, post and at f-up) were matched for multiple 
angiographle views. Over this span of time the restenosis rata (RR) has 
decreased from 20% (BENESTENT-I)to 10% (MUSIC) whil~ the MLD post- 
stem has increased from 2.51 mm (BENESTENT.I) to 2.90 mm (MUSIC) in 
vessels of similar size (3,05 ram) and in pta with comparable demographic 
baseline charactedstlcs. 
24 
f l~O w~w~v~m  
lo 
s r -  ' ,-  • • 
MI;AN M~O-,POsr 1~"~ Cq trY0 
From pmvtous multivariate anslym of (:CA I~n~ter~ it ~ m  that 
LAD, vessel size (VS), MLD~,  ML(~ and g~l~ w~m impatient veri~b!e~ 
for prediction of MLO at l.up and RR, Theoe red,bloc were anew stathllic~lb/ 
festal on a larger population In the meta,analyxte maultfo9 lnlwo multNa~t~ 
models', tn the tlmt model all above menl~o~m:l vaflat,~s w~m leoft~l a~'lmlfog 
gain, whereas in the second MLD.PO~t was ex¢l~e¢l, For model 1~ fogit(n) 
MLDpo=~, The Ho0mer and Lamcshow teM for good--co,el,fit demtmstrates 
the superiority ol modal 2, 
Conc/l~cm: This angl0gmphio meta,analy=is ¢onfimNKI the 'blggef is 
bettor' hypothesis in a very hon~geneoue papu!a~ treated with the eame 
device and analysed a~ordlng to consistent met~a!  appmaO~es in 
the same ang!ographio com,!ab over a period oi 7 years, 
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~ Naurologl©al Events After Su~'enfu l  Carotid 
| | tent ing 
M,W, Llu, G,S, Roubin, A, Msthur, S,S, lyer, L.S, Dean, N,A. AbMubamk, 
J, Vttok, C. Gom~, J, Tetw, G, Yatus, K. Kmt~er, D. Aired Un~JJly ot 
Alaban~1 at Birmingham, B/nmingham. Alabama, USA 
~ckgl~md: Carotid endartorectomy has been shown to ~ neurological 
events in patients with severn extra-cranial internal carotid stenosis, Carotid 
slanting has been lovestigeted as a less tnvaslve alternative treatmem for 
carotid etenosis. The tong.term neurological events alter successful carotid 
slanting have not yet been repotted. 
Methods: From Sep, '94 through Jan '97, them were 228 patients with 
internal carotid stenosls _>60% that unden~ent carotid ~tentlog, Pefcutanoous 
femoral approach was used, Neurological evaluation was padormed by a 
neurologist before anti after the slanting and at 6 month follow-up. Clinical 
follow-up information was obtained in all patients except one. 
Results: Mean age was 68 ~- 10 years. Them were 161 males, 169 
with co-existing severe coronary artery disease. Fo~/patients unden~ent 
bilateral carotid stoning, 27 had a contraisteral occlusion and 132 were 
symptomatic due to the target lesions, Palmaz stents were used in 90 patients 
and Waflstente in 126. The pra and post steeling diameter stonoses were 
77 :t 13% and 3 ± 9%, Five procedures were technical failum,~ and are 
excluded from the survival analysis. Them were 9 procedure related minor 
strokes and 2 major strokes, Follow,up at 14.3 ± 8.5 months (range 6 to 
33 months) showed 4 minor strokes° no maim strokes and one neurological 
death, Cumulative survival free of any stroke or neurological death was 96 
± 1% at hospital discharge, 94 ± 2% at 1 year and 91 ± 3% at 2 years. 
Cumulative survival free of any meier stroke or neurological death was 99 :~ 
1% at hospital discharge, 99 ± 1% at 1 year and 99 ± 1% at 2 years. 
Conclusion: Neurological events after successful carotid stenting appear 
to be ram in toltow-up. This suggests carotid steeling may be an effec- 
tive treatment strategy in preventing stroke in patients with severe carotid 
stenosis, 
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1809-51 S ix-Month Clinical and Angiographle  Results o f  the 
• SMART l~lal 
R. Heuser. R, Kuntz, A. Lansky. K,K.L He. 9. Pino-Mauch. L. Reduto, 
R. Badger, P. Coleman, P, Whitlow, Columbia Medical Center. Phoenix. AZ, 
Beth Israel De~coness Medi¢,~l Center, Boston. MA. USA 
Background: The SMART Tdal is a prospective, randomized, multicenter, 
comparative trial of the AVE Micro'" Steel II and the Palmaz-Schatz '~ (P/S) 
stent in de novo and restenotic oronary lesions up to 30 mm in length. 
Methods: Patients were enrolled and randomized to receive either the 
AVE sfen! (n = 330) or the P/S slant (n = 331), 
JACC l:ebm~n.' I~,~)~ ABSTRACT~ ~ Oral 6~A 
R(~I~:  ~ clinical results elm as foltows: 
Ci,n~ ~u~ AV~ P~s p 
Ac~e proc~lu, ah~-e~ 94.i% ~t.P.~. NS 
Acute Pamon ~ucc~ 99, I% 9~8% 0053 
Aoute ~ ~ 97:1~,, 05.2% NS 
6,,T,~-,~'~ TLR 84% 81% NS 
~t!o~'1MA~ 161% 14,6% N~ 
RVO 2.~1 ~: ~.4 283 ~ 0.,!'t N~ 
P~ma, l-O 2~,  0:~ 2T/~ 046 -~ 005 
( ~ % ~  31x 19 34 i~  N,~ 
T~e ~ ~,m~e ~ ~ ~ , e ~  ~ ~ po=t~p,~,~ 
MLO, 
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N- N i~,  A,- I ~ ,  S. EIAZi. H Wafter, H. i~ l~ le~/L  SCll~,~. 
He ,zz~'n  ~ ~. Medmtr~:;-~ K~t~ ~um n~d~ts der 
~a,. Tec~n~cf~e Um,ws~r. Mun¢~ 
Ths study was camed o~ to a~ess me nmuraJ cou~ Of asymptoma~ 
msteno~ att~ con~ ry implantatmn ot Pa~az Schatz s tm=.  evaluams 
me feaaw-~p m 122 ~ eea~z~lpabents w~'m ~ of 50-75% 
si~ mo,nths a~te~r ste~ implan~Jon. 6~ of me 122 pa~m~ had a second 
a n g ~  ~0~ow--up at 12 moths after ste~ i m ~  Quantities 
o~ona~ ar, g~gra~ vras W~d ~medmt~V ~e~ ~ ~ at 
6and 12 momhs afte~ stem implantalion. 
Ntet. s~em After N'~, t" 
CommW~,nos~l%l 45z121 591=7.7  5441:15-r p-=OOt3 
Mmm~d (ut'~na~ diameter tMlO| 3.0 • 06  124z  04 t 3N6 t 05 p = 00047 
re~ssto~ el resterms~s (3MLD >+03 mm)~ was noted in 24 ot the 62 
pabent=, t0 paUents d~ayeO a process=on (AMID > -0.3 ram). Comr~ry 
angi¢olasty of the scented lesmn was ~ m 5% of ltm 122 paliems 
included m the study, ~ later then 1 year after stenl iml~ardalic~. One 
myocarclial mlatcUon eccuned 286 days. one cardiac clea~ occuned 230 
days after stent ~ l ion .  The 1-year-event kee suneival rate was 98.4%. 
Condeeuon~" The data show tttat he maionty ot ~ t i c  patk~ts 
troth mstenosis Itave a favoreble ang~aphic a.,'KI clinical outo0me. Regres- 
sion of the ang io~ mesures of res~ermsis occurs ~ 6 and 12 
months after stent Implantation i these patients. 
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10:30 • Results of Intracomnary Recombinant Human 
Vascular Endothelial Growth Factor (rhVEGF) 
Administration Trial 
T.D. Henry, K. Rocha-Singh, J.M, Isner, D.J. Kemiakes, FJ. Giordano, 
M. Simons, D.W. Losordo, R.C. Hendel, R.O. Bonow, J.M. Rothman, 
E.R. Bodoas, E.R. McCluskey. Hennepin County Medical Center. 
Minneapofis, MN. Genentech, Inc., So. San Francisco, CA, USA 
Background: Few therapeutic option~" currently exiSt for 10tS with severe coro- 
nary artory disease who have areas of viable but underperfused myocardium 
and who are not optimat candidates for PTCA or CA~G. Atlima! models 
using rhVEGF have demonstrated angiogenesis leading to improvement in 
ischemic myocardium. This is the first human study designed to determine 
~a~¢y a~ I o ~  Of ~ r ~ y  mVEGF tn¢lumo~ ct,~ta mqu~md 
stal~e e~edio~l a~na, a ~ig,~f~-.anl remm~g~  t~/nu¢lea, ~i~ve~= 
t~! ~tuo~y and sul~ottmal canrk4~le~ for PTCA o~ C&BG, ~ mrew~d lwo 
tO.m~r~e trma¢oror, ary infu~mn~ ! cor,,¢en~a,,~or~ f 0.00S, 0,017, 0.050, 
or 0.167 . ~ n  ~ ~ ~ i~r ~ I¢~,I, P h l l ~  
~ ~t the lo~ do=e ~ a 4 ~  m ~ emo= I ~  m¢.mt~e 
emPmm~e~ m fturk~r p~uek~ if1111 ~ m L~ L~tfi~t~  M 
Coe¢tt,~: ~hVI~OF alq~am ~ ~lem~ ~ ¢ommw infumm~ at nl~m 
ana=~enem, 
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~ Kinetleu of  11~,  in Plmmw aml t~ ~ Et~ml 
O f ~ l  Ant~ to l r l~o,  tn Mye l in iC1  
~ plays a ~ sole in l~e ~ 0f acute ~ 
;~,;,=,c;k,,, (Aim). Tumor neoom ~-~o~.,, (TN~) a ~ cytolm~ is 
an mnammatmV t~ger th =~ml  cea ~ To deUm~me ifmWopa e~ 
clm~ m auecmu~ w~ TNF. n~ease m ,~wo, we ~ me al~ra#on= 
~*~th ~ O(mq~  m~.-n~), a~nd m hsanhy ~ by ~ ~  
P~sma TNF~ teve~ were ele~mm m ~ ~ m w,e eagy ~ Of 
AMI (mea~ :~ SE 1.47 + 0.10 n 10-82 ~: 0 .16~1 m control, p < 0.01) 
w~d~ peak vakm at 4 heu~m a~er e~m~t ot cheml pare. TNF~ leve~ wm 
conse~eney h~,=- m pamm~ ~h AMI (V~p cla= in-N~ man in pamm~ 
with AMI (l~lEp class I--Ii) m 4. B. 12 hes after onm~t Of d1~1 pro1 (p < 
0-01l- TNF= le~b fall Itlm~ftm, a~l were ~'~ilar 10 the control value at 
~ m'~ a~r rmm o~ AMI. To c,tra~y ema~ee me role Of TNF. rekm~ m 
~ in~a~ s~,e. Sprague Oa~S rms ~mre mmmd wlrn a momck~ 
an~1~dy (MAb) I0 TNF,, (n = 12) or l~r~r (n = 12). =-~ sul~ected to global 
myoca~rml ischemia-re~r~m. T, ea~1~t v~th TNF=,-M.Ab aecrea=mO the 
am.a of ~ (23.B = 4.5 v~ 47.4 ± 5.3 m buffer-tmaled ra1~, p < 0.01), 
the numb~ of circulating en~othelmi ceils, an index of endoth~ m/my 
(11 7 ~ 0.6 ~ 21.3 +- 1.3~,t, p .: 0.01) and Iq~d T.,e~io~tto~ (mez.sured as 
~ .  22 9 t 2.1 vs 32.6 ~- 4 3 nmotmd p < 0 01). This study 
SHOWS that a. TNFu release occurs eady in the course of AMI, b. higher 
orcu~Ung levem of TNF~ correfme w~ exlenswe cardiac dysfunclmn, and 
c. ml~;o~ ol "rNRz decreases i~a¢t ~m by t~lue~cmg o,-..~o;r~ va~-ular 
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181031 Morphine Mimk:= lachem~ Pmconclitionln0 in 
Human Myocami .m Oudng F tCA 
N.P. Xermpoufos, M Lesser, R. BoI1L ~ of Lou~v~We Meo'Ca/ 
Scho~. Loumwne, K~. USA 
Recent stua~s ~ that ~ receptors rne~te ~ preeon~d~n. 
mg in experimental mmals and that morphine m~mcs this car¢~o~ 
olfect. However, it is unknown wt~er  mOrphine p ~  human my. 
ocardhml. A~o~rd~ngly. 16i~lJents (pts) were ~z~B¢l  to recewe a 10.,rain 
~n(r"acococtary 0C) infusion of serme (controls [C|, n = 8) or moq~hine sulfate 
(MS) (n = 8, 15 p/kg). No hecqodyr~!c ringes w~'re noted dum~g Ihe IC 
infusion of MS. Ten mm after the completion of the IC ~ .  10is underwent 
,'~rcA (three 2~-nin ~ each separatod by 5 min). The ST-~ 
shirts horn baseline in the IC-ECG and in the sudace ECG (S-ECG) were 
measured at the end o! each inflation: X ~. SEM; "P ~ 0 05 vs ¢ontrcls. 
tC-ECG (ram) S-ECG (ram) 
C MS C MS 
Inffatmn I 29~:4 14÷3" 23±4 g±2"  
Innaf~n 2 18~3 15±3 15~3 11 ±2 
Inflation 3 16~3 14+-.3 12"-3 11 ~2 
Dunng the figst inflation, the ST-segment shift in both the IC-ECG and 
S-ECG was significantty attenuated in the MS group compared with controls 
(-51% and -60%). In contrel~, the ST shift was tess dunng the second 
and third inflation than dunng the first, indicating ischemic preconditioning. 
